OCCULT SYSTEMIC NON-HODGKINS-LYMPHOMA (NHL) IN PATIENTS INITIALLY DIAGNOSED AS PRIMARY CENTRAL-NERVOUS-SYSTEM LYMPHOMA (PCNSL) - HOW MUCH STAGING IS ENOUGH

被引:68
作者
ONEILL, BP
DINAPOLI, RP
KURTIN, PJ
HABERMANN, TM
机构
[1] MAYO CLIN & MAYO FDN,DEPT LAB MED & PATHOL,ROCHESTER,MN 55905
[2] MAYO CLIN & MAYO FDN,DIV HEMATOL,ROCHESTER,MN 55905
[3] MAYO CLIN & MAYO FDN,MAYO COMPREHENS CANC CTR,ROCHESTER,MN 55905
关键词
CNS LYMPHOMA; STAGING; SYSTEMIC NON-HODGKINS LYMPHOMA;
D O I
10.1007/BF01054724
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To demonstrate the extent of staging necessary to exclude occult systemic stage IV NHL before making a diagnosis of stage I AE PCNSL. Background: The diagnosis of PCNSL requires the demonstration of malignant lymphocytes within the CNS (usually by biopsy) and finding no evidence of systemic NHL. Different staging approaches have been recommended, ranging from extensive systemic evaluation (including bone marrow examination) to a more focused approach (abdominal and pelvic CT) to no systemic evaluation. We have employed a staging regimen that included: ophthalmologic evaluation (including slit lamp examination); CT of chest, abdomen, and pelvis; bilateral iliac crest aspirate and biopsy; flow cytometry of circulating lymphocytes; and, in men, testicular ultrasound. Design/methods: We carried out a retrospective review of 128 patients entered into the Mayo Lymphoma Project data bank (1975-1994). Results: Between the years 1975 and 1994, five patients (3.9%) were identified who fulfilled criteria for the diagnosis of PCNSL (typical clinical history, pathognomonic neuro-imaging, and histologic proof of NHL in brain tissue) but who had occult systemic NHL on staging (bone marrow 1, abdominal lymph nodes 3), or at autopsy (colon 1). Case histories are presented. Conclusions: Patients with apparent PCNSL may have systemic NHL. Complete staging is essential to the initial management of patients presenting as PCNSL to exclude systemic stage IV disease.
引用
收藏
页码:67 / 71
页数:5
相关论文
共 25 条
[1]   SEQUENTIAL COMBINATION OF SYSTEMIC HIGH-DOSE ARA-C AND ASPARAGINASE FOR THE TREATMENT OF CENTRAL NERVOUS-SYSTEM LEUKEMIA AND LYMPHOMA [J].
AMADORI, S ;
PAPA, G ;
AVVISATI, G ;
PETTI, MC ;
MOTTA, M ;
SALVAGNINI, M ;
MELONI, G ;
MARTELLI, M ;
MONARCA, B ;
MANDELLI, F .
JOURNAL OF CLINICAL ONCOLOGY, 1984, 2 (02) :98-101
[2]  
CRISTEA R, 1994, ANN NEUROL, V36, P294
[3]   PRIMARY CNS LYMPHOMA - COMBINED TREATMENT WITH CHEMOTHERAPY AND RADIOTHERAPY [J].
DEANGELIS, LM ;
YAHALOM, J ;
HEINEMANN, MH ;
CIRRINCIONE, C ;
THALER, HT ;
KROL, G .
NEUROLOGY, 1990, 40 (01) :80-86
[4]  
ERVIN T, 1980, CANCER, V45, P1556, DOI 10.1002/1097-0142(19800401)45:7<1556::AID-CNCR2820450707>3.0.CO
[5]  
2-B
[6]   DIAGNOSIS OF PRIMARY CEREBRAL LYMPHOMA WITH PARTICULAR REFERENCE TO CT-GUIDED STEREOTAXIC BIOPSY [J].
FEIDEN, W ;
BISE, K ;
STEUDE, U .
VIRCHOWS ARCHIV A-PATHOLOGICAL ANATOMY AND HISTOPATHOLOGY, 1990, 417 (01) :21-28
[7]   SUCCESSFUL HIGH-DOSE INTRAVENOUS CYTARABINE TREATMENT OF PARENCHYMAL BRAIN INVOLVEMENT FROM MALIGNANT-LYMPHOMA [J].
FRICK, JC ;
HANSEN, RM ;
ANDERSON, T ;
RITCH, PS .
ARCHIVES OF INTERNAL MEDICINE, 1986, 146 (04) :791-792
[8]   PREIRRADIATION METHOTREXATE CHEMOTHERAPY OF PRIMARY CENTRAL-NERVOUS-SYSTEM LYMPHOMA - LONG-TERM OUTCOME [J].
GLASS, J ;
GRUBER, ML ;
CHER, L ;
HOCHBERG, FH .
JOURNAL OF NEUROSURGERY, 1994, 81 (02) :188-195
[9]   PRIMARY CENTRAL NERVOUS-SYSTEM LYMPHOMA [J].
HOCHBERG, FH ;
MILLER, DC .
JOURNAL OF NEUROSURGERY, 1988, 68 (06) :835-853
[10]   CENTRAL NERVOUS-SYSTEM LYMPHOMA - HISTOLOGIC TYPES AND CT APPEARANCE [J].
JACK, CR ;
ONEILL, BP ;
BANKS, PM ;
REESE, DF .
RADIOLOGY, 1988, 167 (01) :211-215